Search

Your search keyword '"Palomique, Juvelyn"' showing total 5 results
Start Over Author "Palomique, Juvelyn" Publisher escholarship, university of california
5 results on '"Palomique, Juvelyn"'

1. HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma

Author

Sun, Na, Zhang, Ceng, Lee, Yi‐Te, Tran, Benjamin V, Wang, Jing, Kim, Hyoyong, Lee, Junseok, Zhang, Ryan Y, Wang, Jasmine J, Hu, Junhui, Zhang, Zhicheng, Alsudaney, Manaf S, Hou, Kuan‐Chu, Tang, Hubert, Zhang, Tiffany X, Liang, Icy Y, Zhou, Ziang, Chen, Mengxiang, Yeh, Angela Hsiao‐Jiun, Li, Wenyuan, Zhou, Xianghong Jasmine, Chang, Helena R, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Noureddin, Mazen, Ayoub, Walid S, Kuo, Alexander, Sundaram, Vinay, Al‐Ghaieb, Buraq, Palomique, Juvelyn, Kosari, Kambiz, Kim, Irene K, Todo, Tsuyoshi, Nissen, Nicholas N, Tomasi, Maria Lauda, You, Sungyong, Posadas, Edwin M, Wu, James X, Wadehra, Madhuri, Sim, Myung‐Shin, Li, Yunfeng, Wang, Hanlin L, French, Samuel W, Lu, Shelly C, Wu, Lily, Pei, Renjun, Liang, Li, Yang, Ju Dong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Liver Cancer, Prevention, Liver Disease, Cancer, Clinical Research, Digestive Diseases, Rare Diseases, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Biomarkers, Tumor, Extracellular Vesicles, Membrane Proteins, Electrocardiography, Glypicans, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsThe sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay for early detection of HCC.Approach and resultsTissue microarray was used to evaluate four potential HCC-associated protein markers. An HCC EV surface protein assay, composed of covalent chemistry-mediated HCC EV purification and real-time immuno-polymerase chain reaction readouts, was developed and optimized for quantifying subpopulations of EVs. An HCC EV ECG score, calculated from the readouts of three HCC EV subpopulations ( E pCAM + CD63 + , C D147 + CD63 + , and G PC3 + CD63 + HCC EVs), was established for detecting early-stage HCC. A phase 2 biomarker study was conducted to evaluate the performance of ECG score in a training cohort ( n  = 106) and an independent validation cohort ( n  = 72).Overall, 99.7% of tissue microarray stained positive for at least one of the four HCC-associated protein markers (EpCAM, CD147, GPC3, and ASGPR1) that were subsequently validated in HCC EVs. In the training cohort, HCC EV ECG score demonstrated an area under the receiver operating curve (AUROC) of 0.95 (95% confidence interval [CI], 0.90-0.99) for distinguishing early-stage HCC from cirrhosis with a sensitivity of 91% and a specificity of 90%. The AUROCs of the HCC EV ECG score remained excellent in the validation cohort (0.93; 95% CI, 0.87-0.99) and in the subgroups by etiology (viral: 0.95; 95% CI, 0.90-1.00; nonviral: 0.94; 95% CI, 0.88-0.99).ConclusionHCC EV ECG score demonstrated great potential for detecting early-stage HCC. It could augment current surveillance methods and improve patients' outcomes.

Published
2023

2. Covalent Chemistry‐Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma

Author

Sun, Na, Lee, Yi‐Te, Kim, Minhyung, Wang, Jasmine J, Zhang, Ceng, Teng, Pai‐Chi, Qi, Dongping, Zhang, Ryan Y, Tran, Benjamin V, Lee, Yue Tung, Ye, Jinglei, Palomique, Juvelyn, Nissen, Nicholas N, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Posadas, Edwin M, Liang, Li, Pei, Renjun, Yang, Ju Dong, You, Sungyong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen

Subjects
Digestive Diseases, Genetics, Prevention, Rare Diseases, Liver Disease, Biotechnology, Cancer, Clinical Research, Liver Cancer, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, circulating tumor cells, click chemistry, hepatocellular carcinoma, nanosubstrate, transcriptome profiling
Abstract

Transcriptomic profiling of tumor tissues introduces a large database, which has led to improvements in the ability of cancer diagnosis, treatment, and prevention. However, performing tumor transcriptomic profiling in the clinical setting is very challenging since the procurement of tumor tissues is inherently limited by invasive sampling procedures. Here, we demonstrated the feasibility of purifying hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from clinical patient samples with improved molecular integrity using Click Chips in conjunction with a multimarker antibody cocktail. The purified CTCs were then subjected to mRNA profiling by NanoString nCounter platform, targeting 64 HCC-specific genes, which were generated from an integrated data analysis framework with 8 tissue-based prognostic gene signatures from 7 publicly available HCC transcriptomic studies. After bioinformatics analysis and comparison, the HCC CTC-derived gene signatures showed high concordance with HCC tissue-derived gene signatures from TCGA database, suggesting that HCC CTCs purified by Click Chips could enable the translation of HCC tissue molecular profiling into a noninvasive setting.

Published
2021

3. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.

Author

Sun, Na, Lee, Yi-Te, Zhang, Ryan Y, Kao, Rueihung, Teng, Pai-Chi, Yang, Yingying, Yang, Peng, Wang, Jasmine J, Smalley, Matthew, Chen, Pin-Jung, Kim, Minhyung, Chou, Shih-Jie, Bao, Lirong, Wang, Jing, Zhang, Xinyue, Qi, Dongping, Palomique, Juvelyn, Nissen, Nicolas, Han, Steven-Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Markovic, Daniela, Elashoff, David, Yu, Hsiao-Hua, Li, Huiying, Heaney, Anthony P, Posadas, Edwin, You, Sungyong, Yang, Ju Dong, Pei, Renjun, Agopian, Vatche G, Tseng, Hsian-Rong, and Zhu, Yazhen

Subjects
Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, Disease Progression, Dimethylpolysiloxanes, RNA, Messenger, Diagnosis, Differential, Neoplasm Staging, Microfluidic Analytical Techniques, Case-Control Studies, ROC Curve, Reverse Transcriptase Polymerase Chain Reaction, Nanostructures, Computer Simulation, Aged, Middle Aged, Female, Male, Nanowires, Early Detection of Cancer, Lab-On-A-Chip Devices, Hep G2 Cells, Click Chemistry, Extracellular Vesicles, Biomarkers, Tumor, Liquid Biopsy, Computational Chemistry
Abstract

We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).

Published
2020

4. Education to Reduce Inappropriate Use of Proton Pump Inhibitors in Patients with Cirrhosis

Author

Palomique, Juvelyn

Subjects
Nursing, Cirrhosis, Decompensation, Deprescribe, Education, Hepatology stewardship, PPI
Abstract

Background: Inappropriate use of proton pump inhibitors (PPI) is common in patients with cirrhosis. PPIs are associated with deleterious effects in cirrhosis including increased risk for hepatic encephalopathy, spontaneous bacterial peritonitis, and liver-related mortality. Objectives: The aim was to decrease the incidence of low-value, non-guideline supported prescription of PPIs in the inpatient setting with a PPI Clinician Update education and a PPI stewardship by Hepatology. Methods: The study was implemented in a single inpatient transplant center. Key medical staff were identified to receive a PPI Clinician Update educational session, including Hospitalist, Gastroenterology fellows, Hepatology and Liver transplant advanced practice provider (APP). Patient data providing incidence of inappropriate PPI prescription was evaluated under a non-equivalent group pre-posttest design. The study used a one group pre-posttest design for assessing change in provider knowledge levels. A designated hepatology APP steward reviewed all PPI prescription appropriateness. Inappropriate PPI prescription was discontinued by the Hepatology APP who provided constructive feedback to the providers. The primary outcome measure was the incidence of inappropriate PPI prescription before and after the education session which were compared using a chi square test. Secondary outcome was percentage of correct responses (from a total of 10 questions), with before- and after-education measures compared using a paired t-test. Results: Twenty-six providers completed the educational session and pre-posttest. Lack of knowledge regarding outpatient PPI indication was reported as the main barrier to verifying PPI prescription. There was a statistically significant 20% increase in knowledge (p < .001) one month after receiving the educational intervention. There was a decrease in the incidence of inappropriate PPI use from 52% (23/44) to 25% (11/44) (p = .009) one month after receiving the educational intervention. The most common reason for inappropriate PPI prescription was continuation of the patient’s home medication without verifying the indication. The posttest survey showed that 46% of clinicians strongly agreed that their practice changed after the educational intervention and constructive feedback. Conclusion: The most common reason for inappropriate PPI prescription was due to a continuation of a home medication without verifying the indication. A multifaceted approach including an educational intervention and hepatology stewardship was effective in increasing knowledge and decreasing the inappropriate PPI prescriptions in the inpatient setting.

Published
2021

5. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma.

Author

Lee, Junseok, Lee, Junseok, Zhang, Ryan, Wang, Jasmine, Hu, Junhui, Zhang, Zhicheng, Alsudaney, Manaf, Hou, Kuan-Chu, Tang, Hubert, Zhang, Tiffany, Liang, Icy, Zhou, Ziang, Chen, Mengxiang, Yeh, Angela, Li, Wenyuan, Zhou, Xianghong, Chang, Helena, Han, Steven-Huy, Noureddin, Mazen, Ayoub, Walid, Kuo, Alexander, Sundaram, Vinay, Al-Ghaieb, Buraq, Palomique, Juvelyn, Kosari, Kambiz, Kim, Irene, Todo, Tsuyoshi, Nissen, Nicholas, Tomasi, Maria, You, Sungyong, Posadas, Edwin, Wu, James, Wadehra, Madhuri, Sim, Myung-Shin, Li, Yunfeng, Sun, Na, Zhang, Ceng, Lee, Yi-Te, Tran, Benjamin, Wang, Jing, Finn, Richard, Saab, Sammy, French, Samuel, Wu, Lily, Pei, Renjun, Liang, Li, Yang, Ju, Agopian, Vatche, Tseng, Hsian-Rong, Busuttil, Ronald, Wang, Hanlin, Lu, Shelly, Zhu, Yazhen, Sadeghi, Saeed, Kim, Hyoyong, Lee, Junseok, Lee, Junseok, Zhang, Ryan, Wang, Jasmine, Hu, Junhui, Zhang, Zhicheng, Alsudaney, Manaf, Hou, Kuan-Chu, Tang, Hubert, Zhang, Tiffany, Liang, Icy, Zhou, Ziang, Chen, Mengxiang, Yeh, Angela, Li, Wenyuan, Zhou, Xianghong, Chang, Helena, Han, Steven-Huy, Noureddin, Mazen, Ayoub, Walid, Kuo, Alexander, Sundaram, Vinay, Al-Ghaieb, Buraq, Palomique, Juvelyn, Kosari, Kambiz, Kim, Irene, Todo, Tsuyoshi, Nissen, Nicholas, Tomasi, Maria, You, Sungyong, Posadas, Edwin, Wu, James, Wadehra, Madhuri, Sim, Myung-Shin, Li, Yunfeng, Sun, Na, Zhang, Ceng, Lee, Yi-Te, Tran, Benjamin, Wang, Jing, Finn, Richard, Saab, Sammy, French, Samuel, Wu, Lily, Pei, Renjun, Liang, Li, Yang, Ju, Agopian, Vatche, Tseng, Hsian-Rong, Busuttil, Ronald, Wang, Hanlin, Lu, Shelly, Zhu, Yazhen, Sadeghi, Saeed, and Kim, Hyoyong

Abstract

BACKGROUND AND AIMS: The sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay for early detection of HCC. APPROACH AND RESULTS: Tissue microarray was used to evaluate four potential HCC-associated protein markers. An HCC EV surface protein assay, composed of covalent chemistry-mediated HCC EV purification and real-time immuno-polymerase chain reaction readouts, was developed and optimized for quantifying subpopulations of EVs. An HCC EV ECG score, calculated from the readouts of three HCC EV subpopulations ( E pCAM + CD63 + , C D147 + CD63 + , and G PC3 + CD63 + HCC EVs), was established for detecting early-stage HCC. A phase 2 biomarker study was conducted to evaluate the performance of ECG score in a training cohort ( n  = 106) and an independent validation cohort ( n  = 72).Overall, 99.7% of tissue microarray stained positive for at least one of the four HCC-associated protein markers (EpCAM, CD147, GPC3, and ASGPR1) that were subsequently validated in HCC EVs. In the training cohort, HCC EV ECG score demonstrated an area under the receiver operating curve (AUROC) of 0.95 (95% confidence interval [CI], 0.90-0.99) for distinguishing early-stage HCC from cirrhosis with a sensitivity of 91% and a specificity of 90%. The AUROCs of the HCC EV ECG score remained excellent in the validation cohort (0.93; 95% CI, 0.87-0.99) and in the subgroups by etiology (viral: 0.95; 95% CI, 0.90-1.00; nonviral: 0.94; 95% CI, 0.88-0.99). CONCLUSION: HCC EV ECG score demonstrated great potential for detecting early-stage HCC. It could augment current surveillance methods and improve patients outcomes.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results